Company Encyclopedia
View More
name
Acurx Pharmaceuticals
ACXP.US
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company’s lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia; and CCP, multiple product candidates for gram-positive infections. Acurx Pharmaceuticals, Inc.
1.875 T
ACXP.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    New to The Street Airs Landmark Show #700 Today at 6:30 PM ET on Bloomberg Television

    New to The Street airs its landmark Show #700 today at 6:30 PM ET on Bloomberg Television. The episode features companies like Lionscrest Advisors, DataVault AI, Pudgy Penguins, Peer To Peer Network, and Acurx Pharmaceuticals. This milestone highlights the platform's expansion across various media, showcasing innovative companies in technology, finance, healthcare, and consumer culture. New to The Street is a leading financial media platform with a strong presence on YouTube and national cable, offering significant visibility for emerging and established brands.

    Acceswire·
    US
    ACXP
    +11.25%
    Acceswire·
    US
    ACXP
    +11.25%

    Acurx Pharmaceuticals: Promising Developments and Strategic Advances in Antibiotic Innovation

    Analyst Jason McCarthy from Maxim Group maintains a Buy rating on Acurx Pharmaceuticals with a $30 price target, citing promising developments in ibezapolstat, a new antibiotic class targeting C. difficile infection. The drug shows low gut microbiome disruption and high clinical cure rates in Phase 2b trials. Positive regulatory feedback supports Phase 3 trials. McCarthy's optimistic outlook is shared by H.C. Wainwright, which also rates the stock as Buy with a $31 target.

    Tip Ranks·
    US
    ACXP
    +11.25%
    Tip Ranks·
    US
    ACXP
    +11.25%

    Acurx Pharmaceuticals Reports Q3 2025 Financial Results

    Acurx Pharmaceuticals (ACXP) reported its Q3 2025 financial results, showing improved cash reserves of $5.9 million, up from $3.7 million in 2024. The company incurred a net loss of $1.99 million, down from $2.82 million year-over-year, with total operating expenses reduced to $2.03 million. Acurx raised $7.8 million through financing activities and is focused on advancing its lead product, ibezapolstat, while acknowledging the need for further funding to achieve profitability.

    Tip Ranks·
    US
    ACXP
    +11.25%
    Tip Ranks·
    US
    ACXP
    +11.25%

    Optimistic Buy Rating for Acurx Pharmaceuticals Driven by Promising Developments and Financial Strength

    Acurx Pharmaceuticals received a Buy rating from analyst Matthew Keller of H.C. Wainwright, with a price target of $31.00. This positive outlook is driven by significant developments in the company's lead compound, ibezapolstat (IBZ), including increased visibility through publications and presentations. Acurx is also exploring financing opportunities to expedite IBZ's development, supported by a recent warrant exercise that boosted cash reserves. Preclinical data presented at IDWeek ’25 showcased IBZ's unique properties, enhancing its potential in treating challenging bacterial infections.

    Tip Ranks·
    US
    ACXP
    +11.25%
    Tip Ranks·
    US
    ACXP
    +11.25%

    Acurx Pharma Q3 net loss narrows to $2 mln

    Acurx Pharma reported a Q3 net loss of $2 million, with an EPS of -$1.23. R&D expenses fell to $0.4 million due to reduced manufacturing and consulting costs. The company completed a 1-for-20 reverse stock split to regain Nasdaq compliance. Analysts maintain a "buy" rating on the stock, with a median 12-month price target of $30.50, representing an 81.7% upside from its last closing price of $5.58.

    Reuters·
    US
    ACXP
    +11.25%
    Reuters·
    US
    ACXP
    +11.25%